228 related articles for article (PubMed ID: 36556427)
1. The Therapeutic Role of SGLT-2 Inhibitors in Acute Heart Failure: From Pathophysiologic Mechanisms to Clinical Evidence with Pooled Analysis of Relevant Studies across Safety and Efficacy Endpoints of Interest.
Patoulias D; Fragakis N; Rizzo M
Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556427
[TBL] [Abstract][Full Text] [Related]
2. The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure.
Stachteas P; Nasoufidou A; Patoulias D; Karakasis P; Karagiannidis E; Mourtzos MA; Samaras A; Apostolidou X; Fragakis N
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542096
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies.
Biegus J; Fudim M; Salah HM; Heerspink HJL; Voors AA; Ponikowski P
Eur J Heart Fail; 2023 Sep; 25(9):1526-1536. PubMed ID: 37477086
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
5. Sodium-glucose Cotransporter 2 Inhibitors: The Impact on Development and Progression of Heart Failure.
Papademetriou V; Geladari E
Cardiovasc Hematol Disord Drug Targets; 2018; 18(2):127-133. PubMed ID: 29618313
[TBL] [Abstract][Full Text] [Related]
6. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
[TBL] [Abstract][Full Text] [Related]
7. Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence.
Natali A; Nesti L; Tricò D; Ferrannini E
Cardiovasc Diabetol; 2021 Sep; 20(1):196. PubMed ID: 34583699
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(1):351-359. PubMed ID: 33503584
[TBL] [Abstract][Full Text] [Related]
9. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
Nassif ME; Kosiborod M
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
[TBL] [Abstract][Full Text] [Related]
10. Effects of sodium-glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta-analysis of randomized controlled trials.
Zheng C; Lin M; Chen Y; Xu H; Yan L; Dai H
Cardiovasc Diabetol; 2021 Apr; 20(1):83. PubMed ID: 33888126
[TBL] [Abstract][Full Text] [Related]
11. Heart failure hospitalization with SGLT-2 inhibitors: a systematic review and meta-analysis of randomized controlled and observational studies.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2019 Apr; 12(4):299-308. PubMed ID: 30817235
[TBL] [Abstract][Full Text] [Related]
12. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Butler J; Handelsman Y; Bakris G; Verma S
Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
[TBL] [Abstract][Full Text] [Related]
13. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
Sharma A; Wu J; Ezekowitz JA; Felker GM; Udell JA; Heidenreich PA; Fonarow GC; Mahaffey KW; Hernandez AF; DeVore AD
ESC Heart Fail; 2020 Feb; 7(1):274-278. PubMed ID: 31747132
[TBL] [Abstract][Full Text] [Related]
14. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
15. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
Cavender MA; Norhammar A; Birkeland KI; Jørgensen ME; Wilding JP; Khunti K; Fu AZ; Bodegård J; Blak BT; Wittbrodt E; Thuresson M; Fenici P; Hammar N; Kosiborod M;
J Am Coll Cardiol; 2018 Jun; 71(22):2497-2506. PubMed ID: 29852973
[TBL] [Abstract][Full Text] [Related]
16. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
[TBL] [Abstract][Full Text] [Related]
17. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
Pan X; Xu S; Li J; Tong N
Front Endocrinol (Lausanne); 2020; 11():599355. PubMed ID: 33335511
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals.
Huang CY; Lee JK
Diabetes Obes Metab; 2020 Dec; 22(12):2348-2355. PubMed ID: 32744411
[TBL] [Abstract][Full Text] [Related]
19. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
20. SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.
Imprialos K; Faselis C; Boutari C; Stavropoulos K; Athyros V; Karagiannis A; Doumas M
Curr Pharm Des; 2017; 23(10):1510-1521. PubMed ID: 28120716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]